Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Yervoy + platinum doublet
nivolumab + ipilimumab + platinum-doublet chemotherapy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment for adults with metastatic or recurrent non-small cell lung cancer without EGFR or ALK genomic tumor aberrations, using two cycles of platinum-doublet chemotherapy with nivolumab and ipilimumab.
LAMPGEN ANALYSIS
Why it matters
Added a dual immunotherapy regimen with a short initial chemotherapy course and no PD-L1 cutoff.
What research teams should watch
Separate the two chemotherapy cycles from the continuing immunotherapy schedule and document driver status.
PRIMARY RECORDS